Please login to the form below

MabThera

This page shows the latest MabThera news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Revlimid (lenalidomide) has been recommended for use with Roche’s MabThera (rituximab) – also known as R2 regimen – for the treatment of adult patients with previously-treated grade 1 to 3A follicular ... Revlimid plus MabThera demonstrated a

Latest news

Roche posts minor sales miss in Q4 as biosimilar pressure grows

All told, the Swiss group’s pharma sales came in at CHF 12bn ($12.35bn), with its ‘big three’ antibodies – Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab) – all on the
Mylan, Biocon’s Herceptin biosimilar launched in US

Alongside Herceptin, this includes Avastin (bevacizumab) and MabThera (rituximab) which are also under threat from new biosimilar launches.
ChemoCentryx surges on phase 3 vasculitis study

At the moment ANCA vasculitis is treated with a combination of potent steroids like prednisolone with immunosuppressive drugs like cyclophosphamide or Roche’s Rituxan/MabThera (rituximab).
Roche wins FDA breakthrough for Gazyva in lupus nephritis

Roche has been counting on a new class of medicines to help offset the biosimilar onslaught on its ageing cancer blockbusters, including Herceptin and MabThera/Rituxan.
New products help lift Roche outlook despite biosimilar onslaught

This was all achieved despite heavy erosion of sales in Europe thanks to biosimilars - the group's total sales fell 4% in the region, with Herceptin revenues down 45% and

More from news
Approximately 17 fully matching, plus 109 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and Herceptin.
Deal Watch November 2016

We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in
Pharma deals in June 2015

Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach. ... Herceptin SC and MabThera SC can be administered in approximately 5 minutes by sc injection
Russian innovation at the crossroads

For example, in autumn 2014, BIOCAD fully pushed out Roche's Mabthera (rituximab) from public procurement.
Pharma deals during December 2014

Subcutaneous formulations of both MabThera and Herceptin based on the Halozyme technology have been launched by Roche.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

Sanofi hires David Loew from Roche

He gradually rose up the ranks at Roche, holding senior marketing positions such as life cycle leader for both MabThera and Xeloda, head of oncology and chief marketing officer, before taking

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Biosimilars: Getting the flock to market

The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....